Praxis Precision Medicines, Inc.
The research page contains a warning that has not been mapped to a supported model interpretation. The company research remains available, but the complete score is withheld until the warning is reviewed.
PRAX · Price history
Price at last available close
$285.48
+$4.48 (+1.59%) 1M
2026-10-28
Tap or drag sideways to inspect a price. Use two fingers to compare automatically. Release to scroll. Use Shift + arrow keys to compare with a keyboard.
Company & revenue
About Praxis Precision Medicines, Inc.
Primary reporting period: 2025-12-31 · Research updated Oct 12, 2026. A research update is not a new financial filing.
Who they are
Praxis Precision Medicines, Inc. is a biopharmaceutical firm operating at the clinical stage, dedicated to creating innovative treatments for central nervous system (CNS) conditions that stem from an imbalance in neuronal activity. The company's primary investigational compounds currently undergoing evaluation include: PRAX-114, an extrasynaptic-preferring positive allosteric modulator of the GABAA receptor, which is currently in Phase IIa clinical trials for addressing both major depressive disorder and perimenopausal depression. Additionally, PRAX-944, a small molecule designed to selectively inhibit T-type calcium channels, is also progressing through Phase IIa clinical trials to manage essential tremor.
How they make money
Praxis Precision Medicines is a clinical-stage biopharmaceutical company that generates no commercial revenue. It focuses on the research and development of novel therapies for central nervous system disorders, relying on capital raises and potential future licensing or collaboration payments to fund its operations.
Products & services
The company develops a pipeline of small molecule and antisense oligonucleotide (ASO) product candidates targeting neurological disorders, including epilepsy and movement disorders.
Brands & revenue mix
Proprietary small molecule platform.
Separate brand revenue is not available in this research.Source
Proprietary antisense oligonucleotide (ASO) platform.
Separate brand revenue is not available in this research.Source
Revenue share is not unit sales or a best-seller ranking. Parent brands and included sub-brands can overlap; do not add overlapping rows.
Product / operating segments
No reconciled product or operating-segment revenue breakdown is available for the current research period. Company-wide revenue remains separate from segment disclosure.
Geographic revenue
No reconciled geographic revenue breakdown was confirmed for the current research period.
Customer types
- Healthcare providers and patients with CNS disordersSource
Customer concentration
No quantified customer-concentration disclosure is available in the current saved research.
Suppliers, materials & equipment
- Contract Research Organizations (CROs) and Contract Manufacturing Organizations (CMOs) — The company relies on third-party vendors for clinical trial management, data collection, and the manufacturing of drug candidates for clinical use; specific supplier names are not disclosed.Source
Competitors
- Biopharmaceutical and biotechnology companies — The company competes with various entities developing therapies for epilepsy and movement disorders, including large pharmaceutical companies and smaller biotech firms.Source
Strengths
- Proprietary small molecule (Cerebrum) and ASO (Solidus) platformsSource
Sources
Company-specific research
Questions worth answering for PRAX
These questions are generated from this company's current financial and score data so the page adds context instead of treating the headline score as a stand-alone conclusion.
- •How long can PRAX fund negative free cash flow using its current cash position before it may need more debt or new shares?
- •How is PRAX likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
- •What specifically needs to improve for PRAX to reach sustainable profitability?
- •What future growth or profitability would be needed to justify PRAX's current valuation?
- •What does the current fundamental change risk warning mean for the reliability or interpretation of PRAX's score?
Essential Investment Snapshot
Market Cap
$7.97B
P/E Ratio
-18.5
EPS
$-12.95
52-Week High
$392.70
52-Week Low
$154.45
Beta
2.81
Analyst Target
$575.00
Shares Outstanding
22.5M
Total Debt
$1.1M
Dividend
No current dividend
Liquidation Value / Share
$59.59
Momentum & Volatility Signals
Two different market-behavior signals. Momentum measures direction and trend strength. Volatility measures how large and unstable the price moves are, regardless of direction.
Neutral / mixed momentum
Normal movement
A high momentum score means price has been trending upward with confirming short- and medium-term strength. A low score means downward or weakening momentum.
A high volatility score means larger, less stable price swings. It can happen while a stock is rising or falling, so high volatility is not automatically bullish or bearish.
Important: the volatility score above is based on realized price volatility. Implied volatility (IV) comes from options prices and represents the market's expected future movement. Wall Street Score will keep IV separate and will only display it when a verified options-chain feed is available.
Community Sentiment
0 active · 0 total callsNo personal call yet on PRAX.
Potential upside factors
- +Growth opportunities may come from revenue expansion, margin improvement, new products, market-share gains, and stronger cash flow.
- +Proprietary small molecule (Cerebrum) and ASO (Solidus) platforms.
Potential downside factors
- −Key risks may include competition, margin pressure, debt levels, valuation risk, and changes in demand within the Biotechnology industry.
- −History of operating losses and expectation of future losses.
- −Dependence on third-party manufacturers and clinical trial sites.
- −Uncertainty of clinical trial success and regulatory approval.
These research factors come from saved company research and financial data, not community votes. They are starting points to verify against filings, not buy or sell recommendations.
Create a free account to make a call.
Scores
Click any score for full breakdownWas this stock page easy to understand?
One click helps us improve the research experience. This is not tied to an investment decision.
Score Changes
Score changes will appear once more historical records are available.
Price vs. Value
Valuation unavailableCurrent Price
$285.48
Model Intrinsic Value
—
Difference
—
Margin of Safety
—
Intrinsic value is not currently available for this stock, so valuation can't be calculated.
Financial Charts
Revenue
Additional Metrics
Operating Cash Flow
Total Debt
Total Assets
Net Margin %
Large reported revenue change: +249.5%
Revenue changed sharply from 2023 to 2024. This can reflect a real business change, acquisition, divestiture, discontinued operations, restatement, or reporting-basis change. Compare the underlying filing before treating it as normal growth or decline.
TTM may combine quarters from before and after the event, so its trend can also be distorted.
Free includes 3 annual periods plus available TTM; Premium includes up to 10 annual periods. History depends on available company filings. Swipe the table horizontally to see older periods. A dash means unavailable, not zero.
| Line Item | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | $0.00 | $8.6M | $2.4M | ···· | ···· | ···· | ···· | ···· |
| Cost of Revenue | — | $140K | $152.4M | $86.8M | ···· | ···· | ···· | ···· | ···· |
| Gross Profit | — | -$140K | -$143.9M | -$84.3M | ···· | ···· | ···· | ···· | ···· |
| Research & Development | — | $267.1M | $152.4M | $86.8M | ···· | ···· | ···· | ···· | ···· |
| SG&A Expenses | — | $59.1M | $56.3M | $42.1M | ···· | ···· | ···· | ···· | ···· |
| Operating Expenses | — | $326.1M | $56.3M | $42.1M | ···· | ···· | ···· | ···· | ···· |
| EBITDA | — | -$303.1M | -$182.5M | -$122.8M | ···· | ···· | ···· | ···· | ···· |
| Operating Income | — | -$326.2M | -$200.2M | -$126.4M | ···· | ···· | ···· | ···· | ···· |
| Interest Expense | — | $0.00 | $0.00 | $0.00 | ···· | ···· | ···· | ···· | ···· |
| Income Before Tax | — | -$303.3M | -$182.8M | -$123.3M | ···· | ···· | ···· | ···· | ···· |
| Income Tax Expense | — | $0.00 | $0.00 | $0.00 | ···· | ···· | ···· | ···· | ···· |
| Net Income | — | -$303.3M | -$182.8M | -$123.3M | ···· | ···· | ···· | ···· | ···· |
| Basic EPS | — | $-13.48 | $-10.21 | $-18.69 | ···· | ···· | ···· | ···· | ···· |
| Basic Shares | 29.13M | 22.50M | 17.91M | 6.59M | ···· | ···· | ···· | ···· | ···· |
| Diluted Shares | 29.13M | 22.50M | 17.91M | 6.59M | ···· | ···· | ···· | ···· | ···· |
Earnings Summary
Revenue
$0
Estimate unavailable.
Revenue Beat/Miss
Not available (no estimate stored)
EPS
-$2.87
Estimate unavailable.
EPS Beat/Miss
Not available (no estimate stored)
Debt Change
+44.0%
Cash Change
+201.6%
Margin Change
Not available
Debt and cash show percentage changes versus the comparison period; margin shows the change in percentage points (pp). These are company-wide changes, not per-share amounts.
Financial Changes Since Prior Period
What Improved
- Cash position grew
What Weakened
- Debt increased
Potential Score Impact
Positive indicators included cash levels. Pressure indicators included EPS growth, debt levels. These factors may support or pressure the Revenue, Management, Financial, and Debt categories; this summary does not claim that the stored scores changed.
Stored Earnings Analysis
EPS declined 13.3%. Cash increased 201.6%. Total debt increased 44.0%.
Earnings-Call Transcript
Earnings-call transcript analysis is not currently available.
These results may influence future scores when the next evaluation is completed.
Insider Activity
Guru / Smart Money
Guru Score
7
Smart Money
7
Number of Gurus
1
Total Guru Value
Avg Portfolio Weight
Largest Holder
Largest Holder %
New Positions
Increased Positions
Reduced Positions
Exited Positions
Net Guru Sentiment
Short Interest
Dividend History
Dividend data is not available yet. Missing data does not mean this company pays no dividend.
Conservative Projected Values
3 Years
$———.——
5 Years
$———.——
10 Years
$———.——
Conservative Projection Rate
——%
Conservative Projected Values — price projections derived from actual 10-year adjusted historical returns, conservatively adjusted and capped at 8% annually. These are distinct from the Outperformance Model Score and WallStreetScore.
Conservative Projected Values
Premium unlocks the 3-year, 5-year, and 10-year conservative projected values with full calculation breakdowns based on actual historical returns.
Start 7-Day Free TrialHistorical Outperformance Record
Premium includes stored forecasts and any available evaluated results. Completed results, win rates and calibrated probabilities are shown only when supported records exist; access does not create historical outcomes.
Start 7-Day Free TrialHistorical Trends
3 historical recordsHistorical Score Chart
3 of 3 records shownWall Street Score
Debt Score
Revenue Score
Asset Score
Capital Score
Management Score
Moat Score
Valuation Score
Buffett Score
Intrinsic Value
Value Reference
Margin of Safety %
Related Companies
BiotechnologyNews
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Reviewing Praxis Precision Medicines (NASDAQ:PRAX) & Actinium Pharmaceuticals (NYSE:ATNM)
Praxis Precision Medicines, Inc. (NASDAQ:PRAX) Given Average Recommendation of “Moderate Buy” by Brokerages
Praxis Precision Medicines: Still Potential Upside After Huge Rally (Rating Upgrade)
Rumor Mill · PRAX
Corporate developments & opportunities
No reviewed developments match this filter.
Evidence credibility is not a forecast of stock performance. Rumor Mill is separate from the WSS score.
Related Stock Research
Continue researching this company with related Wall Street Score rankings and investing guides.
Score Alerts
Premium unlocks alerts when a score rises, falls, or reaches your target price.
Start 7-Day Free TrialPortfolio Score
Premium unlocks portfolio scoring, strongest and weakest holdings, and overall margin of safety.
Start 7-Day Free Trial